Evidence map›Paper›PMID 36452225›Full record

SynthesisFrontiers in pharmacology2022

Efficacy and safety of Shexiang Baoxin Pill for stable coronary artery disease: A systematic review and meta-analysis of 42 randomized controlled trials.

Jingjing Wei, Teng Ma, Cheng Zhou, Pengle Hao, Bin Li, Xinlu Wang, Rui Yu, Mingjun Zhu, Yongxia Wang

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 81 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jingjing WeiThe First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China.
Teng MaSecond Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Cheng ZhouThe First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China.
Pengle HaoThe First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China.
Bin LiDepartment of Cardiovascular Diseases, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China.
Xinlu WangDepartment of Cardiovascular Diseases, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China.
Rui YuDepartment of Cardiovascular Diseases, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China.
Mingjun ZhuDepartment of Cardiovascular Diseases, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China.
Yongxia WangDepartment of Cardiovascular Diseases, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China.
First Affiliated Hospital of Henan University · CNTianjin University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

grademeta-analysisrandomized controlled trialsShexiang Baoxin Pillstable coronary artery disease

Identifiers

PMID36452225
PMCPMC9701736
OpenAlexW4309044122

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.